Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA
Open Access
- 7 January 2021
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 19 (1) , 1-12
Abstract
Background: To date, triple-negative breast cancer (TNBC) treatment options are limited because of the loss of target receptors and, as a result, are only managed with chemotherapy. What is worse is that TNBC is frequently developing resistance to chemotherapy. By using small interfering RNA (siRNA)-based therapeutics, our recent work demonstrated X-box-binding protein 1 (XBP1) was linked to human epidermal growth factor receptor 2 positive (HER2+) breast cancer development and chemoresistance. Given the instability, off-target effects, net negative charge, and hydrophobicity of siRNA in vivo utilization and clinical transformation, its use in treatment is hampered. Thus, the development of a siRNA-based drug delivery system (DDS) with ultra-stability and specificity is necessary to address the predicament of siRNA delivery. Results: Here, we assembled RNase resistant RNA nanoparticles (NPs) based on the 3WJ structure from Phi29 DNA packaging motor. To improved targeted therapy and sensitize TNBC to chemotherapy, the RNA NPs were equipped with an epidermal growth factor receptor (EGFR) targeting aptamer and XBP1 siRNA. We found our RNA NPs could deplete XBP1 expression and suppress tumor growth after intravenous administration. Meanwhile, RNA NPs treatment could promote sensitization to chemotherapy and impede angiogenesis in vivo. Conclusions: The results further demonstrate that our RNA NPs could serve as an effective and promising platform not only for siRNA delivery but also for chemotherapy-resistant TNBC therapy.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81601626)
- National Natural Science Foundation of China (31800833)
- National Natural Science Foundation of China (21977081)
- National Natural Science Foundation of China (81703713)
This publication has 47 references indexed in Scilit:
- Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cellsNature Protocols, 2013
- Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeuticsNature Nanotechnology, 2011
- A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell DeathPLOS ONE, 2011
- Pharmacological Characterization of Chemically Synthesized Monomeric phi29 pRNA Nanoparticles for Systemic DeliveryMolecular Therapy, 2011
- Cell-Specific Aptamer-Mediated Targeted Drug DeliveryOligonucleotides, 2010
- Fabrication of Stable and RNase-Resistant RNA Nanoparticles Active in Gearing the Nanomotors for Viral DNA PackagingACS Nano, 2010
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Mechanisms and optimization of in vivo delivery of lipophilic siRNAsNature Biotechnology, 2007
- Human X‐Box binding protein‐1 confers both estrogen independence and antiestrogen resistance in breast cancer cell linesThe FASEB Journal, 2007
- Interfering with disease: a progress report on siRNA-based therapeuticsNature Reviews Drug Discovery, 2007